TickerFactsScreenerDevelopers

Spyre Therapeutics, Inc. (SYRE) — Cash & Equivalents

Annual figures by fiscal year, from SEC filings.

2013: $4.60M2014: $2.62M2015: $29.29M2016: $47.75M2017: $12.82M2018: $22.46M2019: $19.25M2020: $90.09M2021: $15.14M2022: $34.86M2023: $188.89M2024: $89.42M2025: $85.72M$85.72M
2013Cash & Equivalents (USD)2025
Fiscal YearCash & EquivalentsChange YoY
2025$85.72M-4.1%
2024$89.42M-52.7%
2023$188.89M+441.8%
2022$34.86M+130.2%
2021$15.14M-83.2%
2020$90.09M+368.0%
2019$19.25M-14.3%
2018$22.46M+75.2%
2017$12.82M-73.2%
2016$47.75M+63.0%
2015$29.29M+1019.8%
2014$2.62M-43.1%
2013$4.60M—